

INOVIQ RECEIVES \$1.782M R&D TAX INCENTIVE REFUND

Melbourne, Australia, 26 October 2026: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**), a biotechnology company developing next-generation exosome-based diagnostics and therapeutics, is pleased to announce that it has received a \$1.782m Research & Development (R&D) Tax Incentive refund relating to its FY26 R&D activities.

The Australian Government's R&D Tax Incentive program provides companies with a 43.5% refundable tax offset for eligible R&D activities. INOVIQ incurred \$4.1m on R&D activities in FY26 and was able to claim the refund on eligible expenditure which excluded certain overseas based expenditure.

Authorised for release by the INOVIQ Limited Board of Directors.

FURTHER INFORMATION

Peter Gunzburg

Executive Chairman

E peter.gunzburg@gmail.com

M +61 412 927 773

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology advancing next-generation diagnostics and therapeutics that transform cancer care. Our product portfolio includes commercial-stage exosome isolation products, a clinical-stage diagnostic for early detection of ovarian cancer, and a cutting-edge preclinical CAR-exosome therapeutic program for solid tumours. INOVIQ is shaping the future of cancer detection and treatment to improve patient outcomes. For more information on INOVIQ, visit www.inoviq.com.